Clinical Trials Logo

no HLA-identical Donor Available clinical trials

View clinical trials related to no HLA-identical Donor Available.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT01220544 Recruiting - Clinical trials for Acute Myeloid Leukemias

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Start date: July 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation. The effectiveness of allogeneic NK cells is a function of HLA-differences between donor and recipient that give rise to NK cell clones which do not express inhibitory receptors matching for the HLA molecules of the recipient. Aim of the study is to evaluate cellular therapy with alloreactive, IL-2 activated NK cells after transplantation of T-cell depleted stem cell grafts from one haplotype mismatched family donors in patients with hematological malignancies.